• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
moini_ch01_lecture_revised2016
moini_ch01_lecture_revised2016

... (%). (A) These curves show drug potency. Drug A’s curve is to the left of drug B’s curve, which indicates that drug A has a higher potency. This means that a smaller dose of drug A will produce the same effect as a larger dose of drug B. Focus on Pharmacology: Essentials for Health Professionals, Se ...
Beta blocker equivalency table nebivolol
Beta blocker equivalency table nebivolol

... there are actually “three generations of beta-blockers” (Table 1), to vasodilator betablockers, such as carvedilol and nebivolol, which have . Oct 13, 2009. Nebivolol has the highest β1-receptor affinity among β-blockers and, most. . for β1- versus β2-adrenergic receptors of the d-isomer (Table 1)ex ...
Antibiotic Resistance. Because of overuse and misuse, some
Antibiotic Resistance. Because of overuse and misuse, some

... for 6.4 percent of all US prescriptions but only 2.6 percent by value. This discrepancy, paired with the medical need for new antibiotics, has prompted some advocates to push for government intervention in the drug approval process specific to antibiotic development. Some policy makers have suggeste ...
Theme: Antiatherosclerotic drugs.
Theme: Antiatherosclerotic drugs.

... increases the synthesis of VLDL. At the same time, the level of triglycerides, as well as the basal metabolic rate changed little. It is recommended for the treatment of hyperlipoproteinemia of type II and III. The effect of ¬ veins with enteral administration. ...
Drug Repositioning Approaches for the Discovery of New ’s Disease REVIEW
Drug Repositioning Approaches for the Discovery of New ’s Disease REVIEW

... during the period 2001–12) [6, 7]. The high attrition rate for AD drug development is mainly attributed to the failure of predicting the safety and/or efficacy of candidate drugs prior to human testing. Drug repositioning strategies have been suggested as a solution to overcome some of these impendi ...
IN VITRO Review Article  LEENA PATIL*
IN VITRO Review Article LEENA PATIL*

... of Quality assurance, Bharati Vidyapeeth’s College of Pharmacy, C.B.D Belapur, Navi Mumbai 400614, Mumbai India. Email: leena171089@gmail.com Received: 01 Jan 2014, Revised and Accepted: 28 Feb 2014 ...
Enhancement of Dissolution Rate of Naproxen by Lipid Based Solid
Enhancement of Dissolution Rate of Naproxen by Lipid Based Solid

... Oral dosage forms have always been considered the preferred route of delivery due to their lower unit dose cost and ease of compliance. Approximately 40-70% of new chemical entities (NCE’S) display poor oral absorption characteristics, generally as a result of poor solubility, poor dissolution rate ...
Tranquilizer drug forensics - Neuroscience Consulting, Inc
Tranquilizer drug forensics - Neuroscience Consulting, Inc

... caused by tranquilizing drug action are merely the leading edge of an historical wave. In seeking to understand the present context and future direction of this wave it helps to have an historical understanding of the evolution, use, and abuse of these drugs. The 1966 novel Valley of the Dolls by ...
NIDA Prescription Drug Report
NIDA Prescription Drug Report

... their ability to increase GABA activity that they produce a drowsy or calming effect that is beneficial to those suffering from anxiety or sleep disorders. ...
Pharmacokinetics is
Pharmacokinetics is

... School of Bioprocess Engineering ...
Calculating equivalent doses of oral benzodiazepines
Calculating equivalent doses of oral benzodiazepines

... major differences in potency between different benzodiazepines and this difference in potency is important when switching from one benzodiazepine to another (2). Benzodiazepines also differ markedly in the speed in which they are metabolised and eliminated. With repeated daily dosing accumulation oc ...
IND Application Template
IND Application Template

... FDA drug labeling for approved indications should be noted here, with copies of such labeling included in the attachment section of this IND application. Note: If the drug was withdrawn from the market for any reason related to safety or effectiveness, identify the country(ies) where the drug was wi ...
New EUTF drug plan Formulary additions
New EUTF drug plan Formulary additions

... Participants choosing NMHC for their drug benefits will receive new member ID cards and information from NMHC. Drug claims submitted after June 30, 2007 for a participant who chooses the PPO medical plan or the supplemental plan administered by HMSA will deny. The drug benefits for these plan partic ...
a review on: sustained release technology
a review on: sustained release technology

... reduce dosage frequency. However, this is limited, in that drugs with very short biological half-life as it may require excessively large amounts of drug in each dosage unit to maintain sustained effect, forcing the dosage form itself to become limiting large. In general, drugs with half-life shorte ...
Drug Design, Testing, Manufacturing, and Marketing
Drug Design, Testing, Manufacturing, and Marketing

... with all of its genes and DNA had been mapped through the Human Genome Project. Also, there are approximately 300 micro RNAs in the human genome that control different groups of genes and their activities. Researchers have already designed chemicals known as antagomirs that bind to specific micro RN ...
Teacher Notes
Teacher Notes

... tobacco, and other illicit and licit drugs. Students are also asked about how much they use, how they use and their attitudes to alcohol and other drug use. This survey has been collected since 1984, with additional drug related questions added since 1996. The most recent survey conducted in 2014 ...
(neuroleptics, tranquillisers, sedative, lithium salts)
(neuroleptics, tranquillisers, sedative, lithium salts)

... Method of lithium drugs administration It is administered orally Treatment concentration of lithium in blood – 0,6-0,8 mmol/l (not more than 1,5-1,6 mmol/l) The effect develops after few days – 5-6 months Small width of therapeutic action (treatment with lithium drugs needs the same attentiveness f ...
PEC Pipeline: Looking into the Crystal Ball LCDR Joe Lawrence, MSC, USN
PEC Pipeline: Looking into the Crystal Ball LCDR Joe Lawrence, MSC, USN

... – PEC completes analyses and provides recommendations to DoD P&T – DoD P&T considers all alternatives and forwards collective recommendation to TMA director ...
Department of Pharmacology
Department of Pharmacology

...  Each student must be present with the group they have been assigned to.  Student’s attendance during the seminars is mandatory – only 1 unjustified absence during the whole course will be accepted.  The absence during the seminar must be justified by a duly authorised document (doctor’s note, Un ...
Know the facts about drugs
Know the facts about drugs

... Drugs are often described as being either ‘hard’ or ‘soft’ but it’s not as simple as that. Myth “My teenager is moody and losing interest in school – they must be on drugs” Fact Parents often ask how they can tell if their child is using drugs. But you should be careful of lists of signs and sympto ...
Investor Presentation
Investor Presentation

... Regular doses of low-dose naltrexone can be used to increase a patient's endorphin and enkephalin levels. The interaction of naltrexone with microglia cells within the central nervous system is believed to be how the drug exerts its beneficial effects in individuals who suffer from fibromyalgia; thi ...
company announcement
company announcement

... About advisory committee meetings FDA advisory committees are panels of independent experts who advise the FDA on specific questions raised by the FDA as they consider regulatory decisions. The FDA is not bound by the committee's recommendation, but it takes its advice into consideration when review ...
Dr. A. Ramkishan- CDSCO WHO TRS WPU
Dr. A. Ramkishan- CDSCO WHO TRS WPU

... Water system Qualification conti… • Phase 2:– A further test period of two weeks should be spent carrying out further intensive monitoring while deploying all the defined SOPs after the satisfactory completion of phase 1. (The sampling system is same as applied to phase 1). – This approach demonstr ...
ijlbpr_23
ijlbpr_23

... Crohn's disease is thought to be an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation, it is classified as a type of inflammatory bowel disease. The microspheres carrier for the delivery of the dosage form to the colon is composed of physi ...
Ch3 Pharmacokinetics pharmacodynamics
Ch3 Pharmacokinetics pharmacodynamics

... • PASSIVE DIFFUSION: the movement of drug molecules from an area of high to low concentration • __________ the concentration gradient. • The majority of drug movement occurs this way. Drug moves from the site of administration (________ concentration) to other areas of the body (________ concentrati ...
< 1 ... 51 52 53 54 55 56 57 58 59 ... 161 >

Orphan drug

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as extended exclusivity periods, all intended to encourage the development of drugs which might otherwise lack a sufficient profit motive. The assignment of orphan status to a disease and to any drugs developed to treat it is a matter of public policy in many countries, and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development.According to Thomson Reuters in their 2012 publication ""The Economic Power of Orphan Drugs"", there has been increased investing in orphan drug Research and Development partly due to the U. S. Orphan Drug Act (ODA) 1983 and similar Acts in other regions of the world and also driven by ""high-profile philanthropic funding."" The period between 2001 to 2011 was the ""most productive period in the history of orphan drug development, in terms of average annual orphan drug designations and orphan drug approvals."" For the same decade the compound annual growth rate (CAGR) of the orphan drugs was an ""impressive 25.8 percent, compared to only 20.1 percent for a matched control group of non-orphan drugs."" By 2012 the market for orphan drugs was worth USD$637 million compared to the USD$638 million matched control group of non-orphan drugs, Thomson Reuters.By 2012, ""the revenue-generating potential of orphan drugs [was] as great as for non-orphan drugs, even though patient populations for rare diseases are significantly smaller. Moreover, we suggest that orphan drugs have greater profitability when considered in the full context of developmental drivers including government financial incentives, smaller clinical trial sizes, shorter clinical trial times and higher rates of regulatory success.""
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report